Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 1;28(3):435-437.
doi: 10.1158/1078-0432.CCR-21-3739. Epub 2021 Nov 30.

Inevitable Progress-Relying on the Immune System, Not Chance

Assuntina G Sacco  1 , Ezra E W Cohen  2
Affiliations
Comment

Inevitable Progress-Relying on the Immune System, Not Chance

Assuntina G Sacco et al. Clin Cancer Res. .

Abstract

Locoregional recurrence of head and neck cancer after curative therapy portends a poor prognosis even when resectable. Immunotherapy has opened the door to novel strategic approaches in the curative treatment paradigm. Potentially improving outcomes for patients with recurrent, resectable disease through combination immune modulators highlights a new frontier.See related article by Hanna et al., p. 468.

PubMed Disclaimer

Comment on

References

    1. Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022;28:468–78.
    1. Shibata H, Saito S, Uppaluri R. Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Front Oncol. 2021;11:727433.
    1. Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26:5140–52.
    1. Leddon J, Haque S, Gulati S, Allen C, Palackdharry S, Hamilton A, et al. Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: a single-arm phase II multi-institutional study. J Clin Oncol. 2021;39.
    1. Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, et al. Immune biomarkers of response to immune checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2018;30:57–67.

Substances

LinkOut - more resources